A Study of LY3867070 in Healthy Participants

Launched by ELI LILLY AND COMPANY · Jun 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called LY3867070 to see how well it's tolerated by healthy people and what side effects it might cause. Participants will take the medication by mouth, and researchers will conduct blood tests to learn how the body processes the drug and how it affects overall health. The trial is currently looking for volunteers who are healthy, aged between 18 and 75, and meet certain weight and health criteria.

To participate, individuals need to be in good health according to a medical evaluation and have a body weight of at least 45 kg. However, those with a history of severe allergies, certain medical conditions, or who are currently taking specific medications may not be eligible. Participants can expect to be monitored closely throughout the study, which may include some procedures like skin biopsies for certain parts of the trial. This is a great opportunity for healthy volunteers to contribute to medical research and help us understand how new treatments work.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Are overtly healthy as determined by medical evaluation
• • Part C of the study includes only Japanese and Chinese participants
• • Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive
• Exclusion Criteria:
• • Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy
• • Have a significant history or current thyroid disease
• • Have a significant history of or current psychiatric disorders, rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome and hyperaldosteronism), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational medicinal product; or of interfering with the interpretation of data
• • Have used, or intend to use, prescription or nonprescription medication (including dietary supplements, vitamins, herbal supplements such as St. John's wort, traditional Chinese medicine, or alternative medicines), or any medications known to be strong inhibitors and inducers of the genes CYP1A1, CYP1A2, CYP2B6, CYP3A4 and CYP2C19, within 14 days prior to dosing of any study intervention until end of study assessments are complete
• • Are smokers (including electronic cigarettes) within 6 months prior to screening and unwilling to refrain from smoking for the duration of the study.
• • Unwilling to undergo skin biopsies (for Part B only)
• • Are unwilling to have body hair cut or shaved in cases where hair, in the investigator's opinion, could interfere with noninvasive skin patch